Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial.

Fliser D, Dellanna F, Koch M, Wiggenhauser A; PRIMAVERA study group.

Nephrol Dial Transplant. 2017 Feb 1;32(2):279-287. doi: 10.1093/ndt/gfw418.

PMID:
28186540
2.

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD; FIND-CKD Study investigators.

BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6.

3.

Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial.

Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna F, Floege J, Hetzel GR, Kelm M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):108-18. doi: 10.2215/CJN.05560515. Epub 2015 Dec 17.

4.

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W, Thevis M.

J Sep Sci. 2016 Jan;39(2):333-41. doi: 10.1002/jssc.201501060. Epub 2015 Dec 15.

PMID:
26578461
5.

Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.

Dellanna F, Fluck RJ, Lonnemann G, Wild CA, Iwanowitsch A, Meissner R, Audhya P.

Clin Nephrol. 2015 Nov;84(5):280-8. doi: 10.5414/CN108484.

PMID:
26396097
6.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.

PMID:
26325557
7.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

8.

Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study).

Gesualdo L, Combe C, Covic A, Dellanna F, Goldsmith D, London G, Mann JF, Zaoui P, Turner M, Muenzberg M, MacDonald K, Abraham I.

Int Urol Nephrol. 2015 May;47(5):837-45. doi: 10.1007/s11255-015-0970-8. Epub 2015 Apr 17.

9.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

10.

Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.

Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.

Nephrology (Carlton). 2014 May;19(5):266-74. doi: 10.1111/nep.12214.

PMID:
24506498
11.

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.

Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J.

Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23.

12.

[Interdisciplinary interaction in vascular diseases of the eye, diabetes and diabetic retinopathy].

Kleophas W, Dellanna F.

Ophthalmologe. 2014 Jan;111(1):19-22. doi: 10.1007/s00347-013-2913-z. German.

PMID:
24448811
13.

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.

Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G.

Nephrol Dial Transplant. 2014 May;29(5):1061-73. doi: 10.1093/ndt/gft476. Epub 2013 Dec 2.

14.

Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease.

Rammos C, Hendgen-Cotta UB, Sobierajski J, Adamczyk S, Hetzel GR, Kleophas W, Dellanna F, Kelm M, Rassaf T.

Int J Cardiol. 2013 Oct 15;168(6):5249-56. doi: 10.1016/j.ijcard.2013.08.021. Epub 2013 Aug 14.

PMID:
23978362
15.

Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.

De Cock E, Dellanna F, Khellaf K, Klatko W, Maduell F, Raluy-Callado M, Villa G.

J Med Econ. 2013;16(5):648-56. doi: 10.3111/13696998.2013.775133. Epub 2013 Mar 15.

PMID:
23402559
16.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

17.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.

18.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

19.

Efficacy and safety of lanthanum carbonate in German patients on dialysis.

Dellanna F, Reichel H, Seibt F.

Clin Nephrol. 2012 Nov;78(5):382-90. doi: 10.5414/CN107330.

PMID:
22948119
20.

Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study.

Galle J, Kleophas W, Dellanna F, Schmid VH, Forkel C, Dikta G, Krajewski V, Fuchs W, Forst T, Pfützner A.

Nephron Extra. 2012 Jan;2(1):104-14. doi: 10.1159/000337334. Epub 2012 May 4.

Supplemental Content

Loading ...
Support Center